ArticleMethods in molecular biology (Clifton, N.J.)2026
Properties and Application of Pseudotyped Lentiviral Vectors.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lentiviral (LV) vectors derived from human immunodeficiency virus type 1 (HIV-1) mediate efficient gene transfer into various cell types, including neuronal, glial, and neural stem cells in the central nervous system. The HIV-1-based LV vectors commonly used are self-inactivating and pseudotyped with a variety of viral envelope glycoproteins. Pseudotyping with vesicular stomatitis virus glycoprotein (VSV-G) confers broad tropism to wide variety of cells and enhances vector stability of the vectors. Pseudotyping with other glycoproteins alters the tropism. In particular, the use of rabies virus glycoprotein (RV-G) or fusion glycoproteins (FuGs) consisting of VSV-G and RV-G segments increases the efficiency of retrograde gene delivery into neuronal cells. The LV vector strategy provides useful approaches to genetic manipulation of specific neural pathways for elucidating the structure and function of neural circuits, and also to genome-wide screening of key molecules and gene regulatory elements in development and survival of the nervous system. Such a strategy also provides a powerful tool for clinical applications aimed at gene therapy for neurological and neurodegenerative diseases as well as central nervous system tumors.
Indexed as
Identifiers
41273636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.